New drug combo shows promise in early cancer trial
Disease control
Ongoing
This early-phase trial tests a new drug called IOS-1002, given alone or with another cancer drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 140 people will ta…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated May 09, 2026 11:40 UTC